Hypocupremia-related hypochromic anemia during D-penicillamine treatment

Idiopathic hypochromic anemia

Polymyositis complicating D-penicillamine treatment.

Although there is good evidence that D-penicillamine can induce polymyositis, the exact pathogenic mechanism remains unclear. We report two patients with psoriatic arthritis and primary biliary cirrhosis respectively, who developed polymyositis while receiving D-penicillamine treatment for their primary diseases. Whether D-penicillamine treatment was the sole cause of polymyositis or acted as a...

Wilson's disease: assessment of D-penicillamine treatment.

Serum copper and zinc concentrations and 24 hour urinary copper and zinc excretion were determined serially from the beginning of treatment with D-penicillamine in four children with Wilson's disease. The data show a progressive decrease in both serum copper and zinc concentrations in all. Urinary copper excretion gradually levelled off to approximately 50% of initial values, but zinc excretion...

Treatment of scleroderma heart by D-penicillamine.

A case of severe diffuse systemic sclerosis with cardiomegaly and cardiac failure is described. Treatment with D-penicillamine caused a pronounced decrease in heart size, together with clinical improvement. The use of penicillamine in scleroderma heart has not previously been reported.

Metal mediated bilirubin encephalopathy: Treatment with D-Penicillamine

Introduction Our recently published case reports and other healthy and highly educated patients of the long-term (28-42 years) follow-up suggest that D-Penicillamine (D-PA) therapy of newborn infants may have significant neuroprotective effects in cases jeopardized by bilirubin induced neurologic dysfunction (BIND) or retinopathy of prematurity (ROP) [1-3]. The first patient (43 ys) is now a me...